LOUISIANA, 97 TO NOTHING — AND IT STARTS TODAY
Act 956 takes effect TODAY. Louisiana now has a Psychedelic-Assisted Therapy Initiative sitting inside the Department of Health's Office of Behavioral Health, running clinical research into opioid use disorder, co-occurring substance use disorders and treatment-resistant neurological and mental health conditions — using psilocybin, ibogaine and MDMA.
Read the vote before you read anything else. Thirty-seven to zero in the Senate. NINETY-SEVEN TO NOTHING in the House. Not one legislator in the state of Louisiana stood up to oppose a psychedelic therapy programme. And the funding is the part that should stop you: it draws primarily on Louisiana's opioid settlement fund — roughly $600 million, much of it still unallocated. The money extracted from the companies that built the opioid crisis is now paying for iboga to treat it.
The psychedelic story has left the coasts and it is not coming back. This is not a wellness constituency, it is a public-health emergency response, and that is why it passes unanimously in Louisiana when it would still be a fight in California. If you are modelling where this goes, stop watching Oregon and start watching the Gulf. And note the funding mechanism specifically — opioid settlement money is the largest uncommitted public health pot in America and it has just found a use nobody predicted five years ago.
NOT A MEASUREMENT — UNCALIBRATED, UNVALIDATED
